Literature DB >> 22320315

Downregulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia.

Dan-Xia Zhu1, Lei Fan, Rui-Nan Lu, Cheng Fang, Wen-Yi Shen, Zhi-Jian Zou, Yin-Hua Wang, Hua-Yuan Zhu, Kou-Rong Miao, Peng Liu, Wei Xu, Jian-Yong Li.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world. Alterations in microRNAs (miRNAs) expression have been proposed to play a role in CLL pathogenesis. Dicer and Drosha are the main regulators of miRNA biogenesis, and deregulation of their expression has been indicated as a possible cause of miRNA alterations observed in various cancers. To investigate the role of Dicer and Drosha in CLL, we assessed the expression of Dicer and Drosha and their correlation with other prognostic factors, including Binet stages, immunoglobulin heavy chain variable gene (IGHV) mutation status, TP53 mutation status, ZAP-70 protein and CD38 expression level in 165 CLL patients by using real-time polymerase chain reaction methods. Patients with unmutated IGHV genes had significantly lower expression of Dicer than patients with IGHV mutations. The lower expression level of Dicer was also significantly associated with higher level of CD38 and ZAP-70, and more aggressive Binet stage. We also analyzed Dicer expression in different cytogenetic subgroups. Lower Dicer level was found in patients with unfavorable cytogenetic aberrations (deletion in 17p13 or 11q22.3) in contrast to higher level in good risk cytogenetics (deletion in 13q14 as the sole abnormality). Furthermore, the lower expression of Dicer in CLL shows a strong association with shorter overall survival (OS) (P = 0.0046) as well as with reduced treatment free survival (TFS) (P = 0.0006). By contrast, no differences in the expression of Drosha among these groups of patients were observed. Our data suggest that Dicer expression may play an important role in the progression and prognosis of CLL.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22320315     DOI: 10.1111/j.1349-7006.2012.02234.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  27 in total

Review 1.  Dysregulation of microRNA biogenesis machinery in cancer.

Authors:  Akiko Hata; Risa Kashima
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-12-01       Impact factor: 8.250

Review 2.  MicroRNA biogenesis pathways in cancer.

Authors:  Shuibin Lin; Richard I Gregory
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

3.  Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.

Authors:  Julian Wampfler; Elena A Federzoni; Bruce E Torbett; Martin F Fey; Mario P Tschan
Journal:  J Leukoc Biol       Date:  2015-05-19       Impact factor: 4.962

Review 4.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 5.  MicroRNA and cancer.

Authors:  Martin D Jansson; Anders H Lund
Journal:  Mol Oncol       Date:  2012-10-09       Impact factor: 6.603

Review 6.  Applications of Extracellular RNAs in Oncology.

Authors:  Jonathan R Thompson; Jing Zhu; Deepak Kilari; Liang Wang
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

7.  Clinicopathological and prognostic significance of the microRNA processing enzyme DICER1 mRNA expression in colorectal cancer patients.

Authors:  Takuya Akahane
Journal:  Mol Clin Oncol       Date:  2012-11-22

8.  Stop the dicing in hematopoiesis: what have we learned?

Authors:  Mir Farshid Alemdehy; Stefan J Erkeland
Journal:  Cell Cycle       Date:  2012-08-01       Impact factor: 4.534

Review 9.  MicroRNA Processing and Human Cancer.

Authors:  Masahisa Ohtsuka; Hui Ling; Yuichiro Doki; Masaki Mori; George Adrian Calin
Journal:  J Clin Med       Date:  2015-08-21       Impact factor: 4.241

10.  Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations.

Authors:  Ander Aramburu; Isabel Zudaire; María J Pajares; Jackeline Agorreta; Alberto Orta; María D Lozano; Alfonso Gúrpide; Javier Gómez-Román; Jose A Martinez-Climent; Jacek Jassem; Marcin Skrzypski; Milind Suraokar; Carmen Behrens; Ignacio I Wistuba; Ruben Pio; Angel Rubio; Luis M Montuenga
Journal:  BMC Genomics       Date:  2015-10-06       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.